WHO Multicentre Growth Reference Study Group (2006) WHO Child Growth Standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. Merritt RJ, Hack SL, Kalsch M, Olson D (1986) Corticosteroid therapy-induced obesity in children. įoster BJ, Shults J, Zemel BS, Leonard MB (2006) Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome. Korsgaard T, Andersen RF, Joshi S, Hagstrom S et al (2019) Childhood onset steroid sensitive nephrotic syndrome continues into adulthood. Raya K, Parikh A, Webb H, Hothi D (2017) Use of a low-dose prednisolone regimen to treat a relapse of steroid-sensitive nephrotic syndrome in children. īoudin V, Alberti C, Lepayraque AL, Bensman A et al (2012) Mycophenolate mofetil for steroid-dependant nephrotic syndrome: a phase II Bayesian trial.
Gruppen MP, Bouts AH, Jansen-van der Weide MC, Merkus MP et al (2018) A randomized clinical trial indicates that levamisole increases the time to relaps in children with steroid-sensitive nephrotic syndrome. Īzib S, Macher MA, Kwon T, Dechatres A et al (2011) Cyclophosphamide in steroid dependant nephrotic syndrome.
Ĭhan EY, Tullus K (2021) Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimen.
Larkins N, Kim S, Craig J, Hodson E (2016) Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children. Ishikura K, Yoshikawa N, Nakazato H, Sasaki S, Nakanishi K, Matsuyama T, Ito S, Hamasaki Y, Yata N, Ando T, Iijima K, Honda M, Japanese Study Group of Renal Disease in Children (2015) Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial. Skrzypczk P, Panczyk-Tomaszewska M, Roskowska-Blaim M, Wawer Z et al (2014) Long-term outcomes in idiopathic nephrotic syndrome: from childhood to adulthood. Rüth EM, Kemper MJ, Leumann EP, Laube GF et al (2005) Children with steroid-sensitive nephrotic syndrome come of age: long term outcome. Sinha A, Hari P, Sharma PK, Gulati A et al (2012) Disease course in steroid sensitive nephrotic syndrome. Hahn D, Hodson EM, Willis NS, Craig JC (2015) Corticosteroid therapy for nephrotic syndrome in children. Graphical abstractĬhanchlani R, Parekh RS (2016) Ethnic differences in childhood nephrotic syndrome. Our results indicate that children with nephrotic syndrome, despite a need for steroid treatment for active disease, can improve their obesity and overweight and also improve their linear growth from their first to last visit with us. Almost 85% of patients were treated with steroid-sparing drugs. The children had lower BMI SDS at last clinical visit compared to initial assessment. At the last clinical visit, 24% were obese and 17% overweight. At initial assessment, 41.4% of the patients were obese (BMI ≥ 95 th percentile) and 19.5% were overweight (BMI 85 th–95 th percentile). Relapses without significant edema were treated with low-dose steroids and steroid-sparing drugs were used in children with steroid dependency/frequent relapses. The cumulative steroid dose (mg/kg/day) during follow-up was calculated. Rate of change between the final and initial height, weight, and BMI was calculated (Δ score). Height, weight, and BMI SDS were recorded at each visit. The study involved 265 children treated with glucocorticoids for nephrotic syndrome for a mean duration of 43 months (range: 6–167, IQR: 17, 63.3). The objective of this study was to determine the prevalence of obesity and overweight and analyze linear growth in children with nephrotic syndrome. Long-term steroid treatment in children is known to cause obesity and negatively affect growth.